News | December 28, 2023
Elpiscience and Astellas collaborate for novel bispecific macrophage engager
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)